Elliott MJ - Search Results

1

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

Feldmann M, Elliott MJ, Woody JN, Maini RN. Feldmann M, et al. Among authors: elliott mj. Adv Immunol. 1997;64:283-350. doi: 10.1016/s0065-2776(08)60891-3. Adv Immunol. 1997. PMID: 9100984 Review. No abstract available.

2

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.

Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. Maini RN, et al. APMIS. 1997 Apr;105(4):257-63. doi: 10.1111/j.1699-0463.1997.tb00567.x. APMIS. 1997. PMID: 9164467 Review.

3

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.

Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, Feldmann M. Maini RN, et al. Clin Exp Rheumatol. 1993 Mar-Apr;11 Suppl 8:S173-5. Clin Exp Rheumatol. 1993. PMID: 8391952 Review.

4

Targeting TNF alpha for the therapy of rheumatoid arthritis.

Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. Maini RN, et al. Clin Exp Rheumatol. 1994 Nov-Dec;12 Suppl 11:S63-6. Clin Exp Rheumatol. 1994. PMID: 7768056 Review.

5

TNF alpha as a therapeutic target in rheumatoid arthritis.

Feldmann M, Brennan FM, Elliott M, Katsikis P, Maini RN. Feldmann M, et al. Circ Shock. 1994 Aug;43(4):179-84. Circ Shock. 1994. PMID: 7895323 Review.

6

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M. Cope AP, et al. Among authors: elliott mj. J Clin Invest. 1994 Aug;94(2):749-60. doi: 10.1172/JCI117394. J Clin Invest. 1994. PMID: 8040330 Free PMC article.

7

New directions for biological therapy in rheumatoid arthritis.

Elliott MJ, Maini RN. Elliott MJ, et al. Int Arch Allergy Immunol. 1994;104(2):112-25. doi: 10.1159/000236718. Int Arch Allergy Immunol. 1994. PMID: 8199454 Review.

8

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. Taylor PC, et al. Among authors: elliott mj. Arthritis Rheum. 2000 Jan;43(1):38-47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. Arthritis Rheum. 2000. PMID: 10643698 Free article.

9

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Charles P, et al. Among authors: elliott mj. J Immunol. 1999 Aug 1;163(3):1521-8. J Immunol. 1999. PMID: 10415055 Free article. Clinical Trial.

10

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Maini RN, et al. Among authors: elliott mj. Arthritis Rheum. 1998 Sep;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. Arthritis Rheum. 1998. PMID: 9751087 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results